Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
Fragile X Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Scientific Presentations
Publications
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
Oct 09, 2014
Appendix 3B
Sep 24, 2014
Appendix 3B
Sep 24, 2014
Issue of long term incentives
Sep 24, 2014
Neuren to release Rett Syndrome trial results in November
Sep 08, 2014
Enrolment commences in Neuren's Concussion Phase 2 trial
Sep 04, 2014
Investor presentation, 4 September 2014
Aug 29, 2014
Appendix 3B
Aug 28, 2014
Neuren reports 2014 half-year financial results
Aug 28, 2014
Half Yearly Report and Accounts
Aug 15, 2014
Appendix 3B
Previous
1
2
3
4
5
Next
